ARO-DIMER-PA
RNA / oligonucleotide
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07223658 NCT07223658 · Hyperlipidemia; Mixed Registry: NCT07223658 | 1/2 | Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (Up to Week 36) 2027-07 | In progress: results expected 1 Jul 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Mixed Hyperlipidemia: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ARO-DIMER-PA: this drug | Phase 1/2 | RNA / oligonucleotide | PCSK9/APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ezetimibe (Zetia) | Approved | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ebronucimab | Phase 3(overall) | Monoclonal antibody | PCSK9 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ARO-DIMER-PA to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.